A randomized, multicenter controlled trial to compare the efficacy of recombinant human parathyroid hormone (1-34) with elcatonin in postmenopausal women with osteoporosis in China

Chinese Medical Journal

Volumn 122, Issue 24, 2009, Pages 2933-2938

  Zhang, Xiu Zhen ^a   Wang, Bo ^a   Yang, Jun ^a   Xuan, Miao ^a   Song, Li Ge ^a   Li, Hong ^a   Guo, Xiao Hui ^b   Lü, Xiao Feng ^c   Xue, Qing Yun ^d   Yang, Gang Yi ^e   Ji, Qiu He ^f   Shen, Jie ^g   Liu, Zhi Min ^h   Li, Cheng Jiang ⁱ   Wu, Tian Feng ^j   Tong, Xiao Cui ^j   Jia, Yuan ^j  

^a TONGJI UNIVERSITY   (China)

^b PEKING UNIVERSITY FIRST HOSPITAL   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

^d BEIJING HOSPITAL   (China)

^e CHONGQING MEDICAL UNIVERSITY   (China)

^f FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^g FIRST MILITARY MEDICAL UNIVERSITY   (China)

^h SECOND MILITARY MEDICAL UNIVERSITY   (China)

ⁱ ZHEJIANG UNIVERSITY   (China)

^j ZHEJIANG HOSPITAL   (China)

more..

Author keywords

Bone mineral density; Elcatonin; Osteoporosis; Recombinant human parathyroid hormone

Indexed keywords

ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; BIOCHEMICAL MARKER; CALCIUM; CREATININE; ELCATONIN; RECOMBINANT PARATHYROID HORMONE; TELOPEPTIDE;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; BLOOD PRESSURE; BONE DENSITY; BONE TURNOVER; CHINA; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE URINE LEVEL; DISEASE MARKER; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEMUR NECK; HEADACHE; HEART PALPITATION; HEART RATE; HUMAN; HYPERCALCEMIA; LIVER FUNCTION; LUMBAR SPINE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MUSCLE SPASM; NAUSEA AND VOMITING; OSSIFICATION; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN URINE LEVEL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; URBAN AREA;

AGED; CALCITONIN; FEMALE; HUMANS; MIDDLE AGED; OSTEOGENESIS; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; RECOMBINANT PROTEINS;

EID: 74549194497     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2009.24.003     Document Type: Article

References (26)

1. Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocr Metab 2002; 87: 4528-4535.
2. Riggs BL. The problem of osteoporosis-its prevention and treatment. In: Riggs BL, ed. Prevention and treatment of osteoporosis. Lewiston: Hogrefe & Huber; 1992: 9-11.
3. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-1441.
4. Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R. Anabolic actions of parathyroid hormone on bone. Endocr Rev 1993; 14: 690-709.
5. Pettway GJ, Meganck JA, Koh AJ, Keller ET, Goldstein SA, McCauley LK. Parathyroid hormone mediates bone growth through the regulation of osteoblast proliferation and differentiation. Bone 2008; 42: 806-818.
6. Bikle DD, Sakata T, Leary C, Elalieh H, Ginzinger D, Rosen CJ, et al. Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone. J Bone Miner Res 2002; 17: 1570-1578.
7. Demiralp B, Chen HL, Koh AJ, Keller ET, McCauley LK. Anabolic effects of parathyroid hormone during endochondral bone growth are dependent on c-fos. Endocrinology 2002; 143: 4038-4047.
8. Bellido T, Ali AA, Plotkin LI, Fu Q, Gubrij I, Roberson PK, et al. Proteasomal degradation of Runx2 shortens parathyroid hormone induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem 2003; 278: 50259-50272.
9. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC, et al. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 1999; 104: 439-446.
10. Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997; 350: 550-555.
11. Colpan L, Gur A, Cevik R, Nas K, Sarac AJ. The effect of calcitonin on biochemical markers and zinc excretion in postmenopausal osteoporosis. Maturitas 2005; 51: 246-253.
12. Arisawa EAL, Brandao AAH, Almeida JD, Rocha RF. Calcitonin in bone-guided regeneration of mandibles in ovariectomized rats: densitometric, histologic and histomorphometric analysis. Int J Oral Maxillofac Surg 2008; 37: 47-53.
13. Chesnut CH, Majumdar S, Newitt DC, Shields A, Van Pelt J, Laschansky E, et al. Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the Quest study. J Bone Miner Res 2005; 20: 1548-1561.
14. Silverman SL, Azria M. The analgesic role of calcitonin following osteoporotic fracture. Osteoporos Int 2002; 13: 858-867.
15. Silverman SL. Calcitonin. Endocrinol Metab Clin North Am 2003; 32: 273-284.
16. Hwang JS, Tu ST, Yang TS, Chen JF, Wang CJ, Tsai KS. Teriparatide vs. calcitonin in the treatment of Asian postmenopausal women with established osteoporosis. Osteoporos Int 2006; 17: 373-378.
17. Marcus R, Wang O, Satterwhite J, Mitlak B. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 2003; 18: 18-23.
18. Kaufman JM, Orwoll E, Goemaere S, Martin JS, Hossain A, Dalsky GP, et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 2005; 16: 510-516.
19. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003; 349: 1216-1226.
20. Orwoll E, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A. Brief therapy with recombinant human parathyroid hormone (1-34) increases lumbar spine bone mineral density in men with idiopathic or hypogonadal osteoporosis. J Bone Miner Res 2001; 16: S1-S221.
21. Wang SX, Li H. Salmon calcitonin in prevention of osteoporosis in maintenance dialysis patients. Chin Med J 2008; 121: 1280-1284.
22. Crandall C. Parathyroid hormone for treatment of osteoporosis. Arch Intern Med 2002; 162: 2297-2309.
23. Nishida S, Yamaguchi A, Tanizawa T, Endo N, Mashiba T, Uchiyama Y, et al. Increased bone formation by intermittent parathyroid hormone administration is due to the stimulation of proliferation and differentiation of osteoprogenitor cells in bone marrow. Bone 1994; 15: 717-723.
24. Dobnig H, Turner RT. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 1995; 136: 3632-3638.
25. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 1999; 104: 439-446.
26. Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, et al. The effect of teriparatide [Human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003; 18: 9-17.